Haleon Backs Views After Profit Rise on Robust Growth
By Michael Susin
Haleon said pretax profit for 2023 slightly rose supported by better-than-expected sales, with positive volume, price and organic growth across all categories and regions, and backed its targets for 2024.
The consumer-healthcare business, which was spun out of GSK PLC and is partly owned by Pfizer Inc., reported a pretax profit of 1.63 billion pounds ($2.06 billion) compared with GBP1.62 billion a year ago.
However, adjusted pretax profit--which strips out exceptional and other one-off items--fell to GBP2.18 billion from GBP2.265 billion, missing company-provided market expectations of GBP2.215 billion.
Revenue came in at GBP11.30 billion from GBP10.86 billion, ahead of expectations of GBP11.28 billion.
Organic revenue growth rose 8%, consisting of 1.0% volumes and 7.0% price. The company had guided revenue growth to be between 7% to 8%, compared with the market consensus of 7.6%.
Adjusted operating profit rose 10.4% at constant currency to GBP2.55 billion. The company had guided for growth in the range of 9% to 11% at constant currency.
Adjusted operating margin was 22.6%, slightly missing market consensus of 22.7%.
The board declared a final dividend of 4.2 pence a share bringing the total dividend to 6.0 pence a share.
The company backed its 2024 target of organic revenue growth range of 4% to 6%. It also expects organic operating profit growth to be ahead of organic revenue growth.
These are the same targets for the medium term.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
February 29, 2024 02:55 ET (07:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth